TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22405557
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the interval between the first and second dose (from 21 days to 12 months)
Study: 22405557
Drug: HI antibody
Normalized name: Salmonella Typhi antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HI antibody response against the two strains
Study: 22405557
Drug: Neutralizing antibody
Normalized name: Neutralizing antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibody responses and CMI
Study: 22405557
Drug: Overall vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall vaccine
Study: 21236421
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro maturation treatment
Study: 9352699
Drug: Alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 2.5 mg three times daily
Study: 8835055
Drug: Elemental zinc
Normalized name: Zinc, 220 mg (as elemental zinc 50 mg) oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental zinc supplementation in daily dosages of 25‐100 mg po
Study: 1745854
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 0.2 mg
Study: 1745854
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 1.0 mg
Study: 6142748
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol 4 mg
Study: 1745854
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol 8 mg
Study: 7049385
Drug: Standard-dose CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CMF
Study: 7049385
Drug: Low-dose CMF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CMF
Study: 7049385
Drug: Overall CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall CMF (both doses)
Study: 27100859
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the National Cancer Institute publication, 'Facing Forward: Life after Cancer Treatment.'
Study: 25331236
Drug: 1-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Study: 25331236
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Study: 20685495
Drug: OLM/AZL 20/16
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM/AZL 20/16 mg
Study: 20685495
Drug: OLM/AZL 10/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM/AZL 10/8 mg
Study: 18164463
Drug: Nonsurgical therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical therapies
Study: 12094185
Drug: High diuretic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High diuretic doses
Study: 12094185
Drug: Low angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low angiotensin-converting enzyme inhibitor dose
Study: 10333344
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (12-15 g NaCl/day)
Study: 10333344
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (1-3 g NaCl/day)
Study: 8618187
Drug: Two-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose schedule at 1 and 3 months
Study: 8618187
Drug: Two-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose schedule at 2 and 4 months
Study: 8618187
Drug: Two-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose schedule at 2 and 6 months
Study: 8618187
Drug: Two-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose schedule at 4 and 6 months
Study: 8618187
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule at 2, 4, and 6 months
Study: 1941708
Drug: Self-administered DIS
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered DIS (S-DISSI)
Study: 1941708
Drug: Interviewer-administered DIS
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered DIS (I-DISSI)
Study: 1941708
Drug: Traditional interviewer-administered
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional interviewer-administered DIS (T-DIS)
Study: 26313245
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus
Study: 29629619
Drug: Ezetimibe (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (oral formulations)
Study: 28623823
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200mg twice daily
Study: 25855851
Drug: Topical platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical platelet derived growth factor (Regranex)
Study: 25633134
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day
Study: 10684841
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (0.5%)
Study: 8956632
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost (0.005%)
Study: 1578922
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX (Regimen A)
Study: 1578922
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus asparaginase (Regimen B)
Study: 1578922
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given early (Regimen C)
Study: 1578922
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given over the first 16 months of therapy (Regimen D)
Study: 1578922
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment approach for ALL
Study: 3001778
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg suloctidil 3-times daily
Study: 30771333
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing of ranibizumab 0.3 mg every 4 weeks
Study: 20088416
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Luminal 30 mg thrice daily)
Study: 20088416
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (herbal decoction)
Study: 20088416
Drug: Acupuncture, Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, Western medicine, Chinese medicine
Study: 17955107
Drug: sumatriptan/naproxen sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan/naproxen sodium (85 mg sumatriptan and 500 mg naproxen sodium)
Study: 15491092
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5mg/day) with oral hygiene measures (group II)
Study: 15491092
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene measures alone (group I)
Study: 9860069
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) at doses of 75 or 150 mg daily
Study: 7634504
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) for 6 months
Study: 7634504
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement for 12 months
Study: 2571434
Drug: Beta-blockers (metoprolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (metoprolol)
Study: 2571434
Drug: Diuretics (thiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (thiazide based)
Study: 582628
Drug: Oral local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral local anaesthetic (oxethazaine)
Study: 582628
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of local anaesthetic and alkali (Mucaine)
Study: 12525193
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiation therapy (arm 1)
Study: 12525193
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and radiation therapy (arm 2)
Study: 12525193
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (arm 3)
Study: 8751270
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of metronidazole (MTN), 500 mg twice a day
Study: 8751270
Drug: 2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% clindamycin (CLDM) phosphate in a vaginal cream, 5 g once a day for 7 days
Study: 3457171
Drug: 2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sodium fluoride solution
Study: 1882058
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (after placebo treatment)
Study: 6979475
Drug: Cotrimoxazole (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (dose ratio 3:2) for 14 days
Study: 6979475
Drug: Cotrimole (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimole (dose ratio 3:2) for 14 days
Study: 25585479
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy intervention (HT intervention) for 16 weeks, comprising 16 weekly sessions (120 min each) at the community center and 15 minutes per day at participants' homes.
Study: 25585479
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy intervention (HT intervention) for 16 weeks.
Study: 20706740
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy with HAN stimulation (TENStem eco), 30 min at least two times a day for 3 weeks
Study: 20706740
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy with HAN stimulation (TENStem eco)
Study: 10232294
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 fatty acids (9.6 g/d)
Study: 8911127
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention (weekly cognitive individual psychotherapy and bimonthly family counselling)
Study: 6218583
Drug: Clindamycin and
Normalized name: clindamycin and benzoyl peroxide KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and aminoglycoside combination
Study: 30563776
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg per day for 6 months
Study: 27010235
Drug: Revexepride 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 0.02 mg
Study: 27010235
Drug: Revexepride 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 0.1 mg
Study: 27010235
Drug: Revexepride 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 0.5 mg
Study: 24778598
Drug: LMA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMA with cuff pressure limiting 25 cmH₂O (L group)
Study: 10770345
Drug: 500 kcal
Normalized name: inf.formula,urea cycle disordr 6.5 gram-500 kcal/100 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 kcal daily of caloric supplement with peptides and medium-chain triglycerides plus a multivitamin and mineral supplement
Study: 10770345
Drug: 500 kcal
Normalized name: inf.formula,urea cycle disordr 6.5 gram-500 kcal/100 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 kcal of a caloric supplement with whole protein and long-chain triglycerides plus a multivitamin and mineral supplement
Study: 10770345
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplement only
Study: 1678798
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (2.5 mU.kg‐1, min‐1)
Study: 1678798
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (2.5 mU.kg‐1, min‐1)
Study: 1678798
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin and Human insulin
Study: 6881419
Drug: Ornidazole 2
Normalized name: ornidazol
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 2 g in two equal doses
Study: 6881419
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g in two equal doses
Study: 27788949
Drug: Pelvic nodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic nodes and prostate radiation therapy
Study: 27788949
Drug: Prostate-only radiation
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-only radiation therapy
Study: 27788949
Drug: Pelvic nodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic nodes radiation therapy (in low-risk subgroup)
Study: 17272375
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention (EI) group received a biopsychosocial treatment including cognitive behavioral skills training and biofeedback.
Study: 17272375
Drug: Nonintervention (NI)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonintervention (NI) group received treatment as usual (biopsychosocial treatment).
Study: 16055825
Drug: Psychodynamic interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic interpersonal therapy (6 sessions)
Study: 12708702
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose pulsed betamethasone therapy
Study: 12708702
Drug: Need based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Need based oral steroids
Study: 10460365
Drug: Sequential CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential CT
Study: 2564772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of applied tension and applied relaxation
Study: 778775
Drug: Experimental physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental physical therapy program
Study: 778775
Drug: Control physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control physical therapy program
Study: 20434403
Drug: Immediate surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate surgery and best medical therapy
Study: 18215153
Drug: Levodopa-carbidopa (LC)
Normalized name: carbidopa / levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa-carbidopa (LC) with unchanged dosage
Study: 18215153
Drug: Levodopa-carbidopa (LC)
Normalized name: carbidopa / levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa-carbidopa (LC) with reduced dosage by 15-25%
Study: 17030687
Drug: ISIS 301012
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 301012 (50 to 400 mg, single dose followed by 4-week multiple dosing)
Study: 21635675
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisone
Study: 8730339
Drug: Trimethoprim/sulfamethoxazole (T/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (T/S) 2 x 960 mg/day in initial phase WG
Study: 8730339
Drug: Trimethoprim/sulfamethoxazole (T/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (T/S) 2 x 960 mg/day in generalized WG (group A)
Study: 8730339
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after standard therapy (group B)
Study: 8730339
Drug: Trimethoprim/sulfamethoxazole (T/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (T/S) plus low-dose prednisone (group C)
Study: 28004493
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration (IVH)
Study: 1299597
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of amineptine
Study: 6367750
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (D-penicillamine and hydroxychloroquine)
Study: 6367750
Drug: Hydroxychloroquine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine therapy
Study: 30101851
Drug: Febuxostat (urate-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (urate-lowering agent)
Study: 25316503
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 50 mg orally twice a day for 2 weeks before operation and maintained for an extra week postoperatively
Study: 19950088
Drug: Propafenone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 600 mg orally as the initial therapy, with an additional dose of 300 mg after eight hours if needed.
Study: 19950088
Drug: Quinidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (1 mg digoxin IV followed by oral loading of 400 mg followed by 200 mg every two hours).
Study: 15179440
Drug: COX‐2‐selective inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2‐selective inhibitor rofecoxib 25 mg daily for 4 weeks
Study: 15179440
Drug: COX‐2‐selective inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2‐selective inhibitor rofecoxib
Study: 11453892
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg twice daily for 7 days)
Study: 11453892
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg twice daily for 7 days)
Study: 11453892
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg twice daily for 7 days)
Study: 9728825
Drug: Isoproterenol (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (IV injections)
Study: 9155503
Drug: High-carbohydrate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate meal (L, 5.5 g mixed fat/meal)
Study: 9155503
Drug: Moderately high-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high-fat meal (M, 33 g mixed fat/meal)
Study: 2654171
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE), 100 mg/week
Study: 2654171
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE), 300 mg/week
Study: 2654171
Drug: 19-nortestosterone decanoate
Normalized name: 19-nortestosterone decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 19-nortestosterone decanoate (ND), 100 mg/week
Study: 2654171
Drug: 19-nortestosterone decanoate
Normalized name: 19-nortestosterone decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 19-nortestosterone decanoate (ND), 300 mg/week
Study: 31932487
Drug: LA dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA dose
Study: 25588930
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (MPH-SR) 18 to 54 mg/day for 10 weeks